EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudieOpen Access · CC BY-NC 3.0

Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors

Daniel Ejim Uti iD, Wilson Achu Omang, Esther Ugo Alum iD, Okechukwu Paul-Chima Ugwu iD, Margaret Amieibi Wokoma, Rowland Inalegwu Oplekwu, Item Justin Atangwho, Godwin Eneji Egbung

International Journal of Nanomedicine · 2025-08 · Volume 20 · 10101-10126

DOI: 10.2147/ijn.s529250 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2025-08. Verfasst von Daniel Ejim Uti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Publications, Kampala International University, Kampala, Uganda. Hauptthemen laut MEDLINE: Hyaluronic Acid, Hyaluronan Receptors, Obesity, Nanoconjugates. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD44, a key hyaluronic acid (HA) receptor, has emerged as a central mediator of adipose tissue inflammation, remodeling, and insulin resistance in obesity. Its overexpression in obese adipose depots promotes leukocyte infiltration, pro-inflammatory signaling, and extracellular matrix dysregulation processes that underlie metabolic dysfunction. This review explores the therapeutic relevance of targeting the HA-CD44 axis by synthesizing data primarily from preclinical studies, with emerging evidence from early clinical investigations. A narrative review methodology was employed to assess and compare therapeutic modalities, highlighting advances in molecular targeting, drug delivery systems, and metabolic interventions. We focus on two primary therapeutic classes: small molecules and nanobioconjugates. Small molecules, such as curcumin, metformin, and CD44 antagonists, offer systemic modulation and accessibility but are limited by their low tissue specificity and potential side effects. In contrast, HA-functionalized nanobioconjugates, including liposomes, PLGA nanoparticles, dendrimers, and exosomes, enable targeted delivery to adipose tissue, prolonged drug release, and reduced systemic toxicity. These nanosystems have demonstrated superior modulation of CD44 signaling, adipose inflammation, and glucose homeostasis in obesity models. Emerging strategies such as monoclonal antibodies, GLP-1 analogs, gene-editing tools (eg, CRISPR/Cas9), microbiome modulators, and brown adipose tissue (BAT) activators are also discussed. A comparative analysis indicates that nanobioconjugates offer the highest targeting precision, while small molecules remain advantageous in terms of cost and ease of administration. However, biologics and gene therapies face challenges related to delivery and scalability. Collectively, current evidence predominantly preclinical supports the HA-CD44 axis as a promising therapeutic target in obesity. Integrated approaches combining nanotechnology with molecular inhibitors and biologics could offer a multifaceted strategy for managing metabolic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidHyaluronan ReceptorsObesityNanoconjugatesHumansAnimalsSignal TransductionDrug Delivery SystemsAdipose TissueNanoparticles

Stichwörter der Autor:innen

CD44 isoform-specific therapyadipose tissue inflammationmetabolic reprogrammingobesity-associated fibrosistargeted nanomedicine

Substanzen

Hyaluronic AcidHyaluronan ReceptorsNanoconjugatesCD44 protein, human

Autor:innen und Institutionen

  • Department of Research and Publications, Kampala International University, Kampala, Uganda.
  • Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, Federal University of Health Sciences, Otukpo, Benue State, Nigeria.
  • Department of Medical Laboratory Sciences, College of Health Technology, Calabar, Cross River State, Nigeria.
  • Department of Biochemistry, Faculty of Basic Medical Sciences, University of Calabar, Calabar, Nigeria.
  • Department of Biochemistry, Faculty of Basic Medical Sciences, Federal University of Allied Health Sciences, Enugu, Nigeria.

ORCID-Profile: Daniel Ejim Uti, Esther Ugo Alum, Okechukwu Paul-Chima Ugwu

Zitieren

APA

Uti, D. E., Omang, W. A., Alum, E. U., Ugwu, O. P., Wokoma, M. A., Oplekwu, R. I., Atangwho, I. J., & Egbung, G. E. (2025). Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. International Journal of Nanomedicine, Volume 20, 10101-10126. https://doi.org/10.2147/ijn.s529250

Vancouver

Uti DE, Omang WA, Alum EU, Ugwu OP, Wokoma MA, Oplekwu RI, et al. Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. International Journal of Nanomedicine. 2025;Volume 20:10101-10126. doi:10.2147/ijn.s529250

BibTeX
@article{Uti2025,
  author = {Uti, Daniel Ejim and Omang, Wilson Achu and Alum, Esther Ugo and Ugwu, Okechukwu Paul-Chima and Wokoma, Margaret Amieibi and Oplekwu, Rowland Inalegwu and Atangwho, Item Justin and Egbung, Godwin Eneji},
  title = {Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  volume = {Volume 20},
  pages = {10101--10126},
  doi = {10.2147/ijn.s529250}
}
Kostenlos starten →